SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Heightened geopolitical tensions in the Middle East, particularly concerning Iran and Israel, are sparking intense debate around SPY, as initial futures show a relatively muted reaction despite fears of broader conflict. The community is divided between those anticipating a major market crash and others expecting an aggressive 'buy the dip' rebound, fueled by observations of a historically resilient market and rising oil prices.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

INDO is seeing significant discussion as escalating Middle East tensions ignite a surge in oil prices, with the community anticipating a substantial short squeeze driven by concerns over global supply routes and recalling the stock's historic parabolic moves during similar past conflicts.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is trending amidst rising geopolitical conflicts, fueling speculation about increased demand for its drone and counter-UAS technology from global defense sectors, while the community actively discusses the potential for a short squeeze and upcoming contract announcements.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid intense community debate surrounding recent military operations in Iran, with supporters hailing it as a decisive action against perceived threats while critics condemn it as an unlawful conflict and a costly distraction from other controversies. The discussion is heavily polarized, focusing on geopolitical ramifications, potential economic impacts, and the unfortunate American casualties.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp. is trending as escalating Middle East tensions lead to market expectations of surging oil prices and potential supply disruptions, driving community speculation for a strong short squeeze due to the stock's high short interest and recent debt reduction.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending as the community hotly debates escalating Middle East tensions and threats to global oil supply routes, anticipating a significant price surge while also considering the counter-effect of Venezuela's potential oil market reentry.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending amid escalating geopolitical tensions following reports of Iran's Supreme Leader's death from US-Israeli strikes, which has intensified concerns about major oil supply disruptions in the Strait of Hormuz. The community is actively debating whether this will lead to a sustained parabolic rally in oil prices or a short-term "sell the news" reaction.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as escalating geopolitical tensions in the Middle East and concerns over potential oil supply disruptions fuel a sharply divided community sentiment, with some predicting a market crash while others anticipate a swift "buy the dip" rebound.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending amid escalating Middle East tensions, driving community discussion around increased defense spending and potential contract boosts for major players, which is further amplified by the company's strong financial outlook and record backlog.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending due to escalating Middle East tensions impacting global LNG shipping and an anticipated strong earnings report, with the community actively discussing potential price surges and the company's significant undervaluation given its expanding capacity and strategic market position.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharming Group Touts 2025 Sales Surge, Joenja Expansion Plans at Oppenheimer Healthcare Conference

Pharming Group (NASDAQ:PHAR) executives outlined commercial performance, pipeline priorities, and regulatory updates during a presentation at Oppenheimer's 36th Annual Healthcare Conference...

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Drop in Short Interest

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the target of a large decline in short interest in the month of February. As of February 13th, there was short interest totaling...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming...

Pharming Group (NASDAQ:PHAR) Stock Price Up 6.4% - Still a Buy?

Pharming Group (NASDAQ:PHAR) Trading Up 6.4% - Here's What Happened...

FY2025 EPS Estimates for Pharming Group Increased by Analyst

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Investment analysts at HC Wainwright increased their FY2025 earnings estimates for shares of Pharming Group in a note issued to...

Pharming Group Q4 EPS Forecast Increased by HC Wainwright

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Equities research analysts at HC Wainwright increased their Q4 2025 earnings per share estimates for shares of Pharming Group in a note...

<ul class="summary-bullets"><li>FDA feedback focused on dosing and testing questions, not safety or effectiveness concerns.</li><li>Joenja’s existing approval and sales in patients aged 12 and older remain unchanged.</li><li>Pharming said it plans to work with regulators and pursue a resubmission path.</li></ul>Pharming Group shares drew heightened retail chatter on Monday after the company said it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its application to expand the use of Joenja in younger pediatric patients, while signaling confidence it can address the agency’s concerns.<h2 class="st-heading-2">FDA Requests Additional Pediatric Data</h2>Dutch drug developer Pharming announced that it had received a Complete Response Letter from the FDA on its filing for the approval of Joenja in children aged 4-11 with activated phosphoinositide 3-kinase delta syndrome (APDS).APDS is a rare primary immunodeficiency disorder in which the immune system does not function properly, resulting in recurrent infections and other complications associated with immune dysfunction. Pharming’s Joenja is an oral medication indicated to treat APDS.The company said the FDA was concerned that younger children may not be receiving sufficient doses at the proposed levels and requested additional data to confirm appropriate dosing in younger patients. The agency also flagged a technical issue with a manufacturing test and requested additional information.Pharming expressed confidence that it can resolve both inquiries. The company added that it plans to meet with the FDA to discuss next steps for resubmission, including a Type A meeting.<h2 class="st-heading-2">Approval For Older Patients Unaffected</h2>The company emphasized that the Complete Response Letter does not impact Joenja’s existing FDA approval for adult and pediatric patients aged 12 years and older, which has been in place since March 2023.CEO Fabrice Chouraqui said Pharming remains focused on making Joenja available to younger children with APDS, noting that there are currently no approved targeted treatments globally for patients under the age of 12.<h2 class="st-heading-2">Trial Results Backing The Application</h2>The application was backed by data from a late-stage clinical study in children aged 4 to 11. Pharming said that over 12 weeks of treatment, children showed reduced lymph node swelling and healthier immune cell levels, signs that the drug was helping correct the immune problem caused by APDS.Safety data from up to eight months of treatment were also included in the submission. The company said all treatment-emergent adverse events were mild to moderate, no drug-related serious adverse events were reported, and all patients completed the 12-week treatment period.In October 2025, the FDA granted the application Priority Review, citing the potential for significant improvements in the treatment of a serious condition.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Pharming was ‘bullish’ amid ‘high’ message volume ahead of the company’s Virtual Investor Day on Tuesday.One user called the FDA response a “soft” CRL, noting that it focused on dosing and testing issues rather than safety, and that Joenja remains approved and generating revenue for patients aged 12 and older.<stembedurl>https://stocktwits.com/BioSpecialOne/message/643641905</stembedurl>Another user said, “will buy the dip. Hopefully it’s a large drop”<stembedurl>https://stocktwits.com/CrispDry/message/643612689</stembedurl><a href="https://stocktwits.com/symbol/PHAR">U.S.-listed shares of Pharming</a> have surged over 130% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Pharming logo is displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Pharming Stock Draws Retail Buzz After FDA Seeks More Data For Pediatric Immune Drug — Why Investors Aren’t Panicking

The company expressed confidence that it can resolve the FDA’s inquiries. 

Equity

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest...

Pharming Group (OTCMKTS:PHGUF) Sets New 1-Year High - Here's What Happened

Pharming Group (OTCMKTS:PHGUF) Hits New 12-Month High - Time to Buy...

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

Pharming Group N.V. - ADR

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

PHAR
Pharming Group

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PHAR News

PHARPharming Group